- Latest available (Revised)
- Original (As adopted by EU)
Commission Directive 2004/33/ECShow full title
Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components (Text with EEA relevance)
You are here:
What Version
Advanced Features
- Show Geographical Extent(e.g. England, Wales, Scotland and Northern Ireland)
- Show Timeline of Changes
More Resources
Revised version PDFs
- Revised 09/01/20150.28 MB
- Revised 13/04/20110.73 MB
This is a Directive originating from the EU
This is a legislation item that originated from the EU
After exit day there will be three versions of this legislation to consult for different purposes. The legislation.gov.uk version is the version that applies in the UK. The EU Version currently on EUR-lex is the version that currently applies in the EU i.e you may need this if you operate a business in the EU.
The web archive version is the official version of this legislation item as it stood on exit day before being published to legislation.gov.uk and any subsequent UK changes and effects applied. The web archive also captured associated case law and other language formats from EUR-Lex.
Changes over time for: Division 2.
Status:
EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.
2.DEFERRAL CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTSU.K.
The tests and deferral periods indicated by an asterisk (*) are not required when the donation is used exclusively for plasma for fractionation.
2.1.Permanent deferral criteria for donors of allogeneic donationsU.K.
| Cardiovascular disease | Prospective donors with active or past serious cardiovascular disease, except congenital abnormalities with complete cure |
| Central nervous system disease | A history of serious CNS disease |
| Abnormal bleeding tendency | Prospective donors who give a history of a coagulopathy |
| Repeated episodes of syncope, or a history of convulsions | Other than childhood convulsions or where at least three years have elapsed since the date the donor last took anticonvulsant medication without any recurrence of convulsions |
| Gastrointestinal, genitourinary, haematological, immunological, metabolic, renal, or respiratory system diseases | Prospective donors with serious active, chronic, or relapsing disease |
| Diabetes | If being treated with insulin |
| Infectious diseases | Hepatitis B, except for HBsAg-negative persons who are demonstrated to be immune |
| Hepatitis C | |
| HIV-1/2 | |
| HTLV I/II | |
| Babesiosis (*) | |
| Kala Azar (visceral leishmaniasis) (*) | |
| Trypanosomiasis cruzi (Chagas' disease) (*) | |
| Malignant diseases | Except in situ cancer with complete recovery |
| Transmissible spongiform encephalopathies (TSEs), (e.g. Creutzfeldt Jakob Disease, variant Creutzfeldt Jakob Disease) | Persons who have a family history which places them at risk of developing a TSE, or persons who have received a corneal or dura mater graft, or who have been treated in the past with medicines made from human pituitary glands. For variant Creutzfeldt Jacob disease, further precautionary measures may be recommended. |
| Intravenous (IV) or intramuscular (IM) drug use | Any history of non-prescribed IV or IM drug use, including body-building steroids or hormones |
| Xenotransplant recipients | |
| Sexual behaviour | Persons whose sexual behaviour puts them at high risk of acquiring severe infectious diseases that can be transmitted by blood |
2.2.Temporary deferral criteria for donors of allogeneic donationsU.K.
2.2.1.InfectionsU.K.
Duration of deferral periodU.K.
After an infectious illness, prospective donors shall be deferred for at least two weeks following the date of full clinical recovery.
However, the following deferral periods shall apply for the infections listed in the table:
| Brucellosis (*) | 2 years following the date of full recovery |
| Osteomyelitis | 2 years after confirmed cured |
| Q fever (*) | 2 years following the date of confirmed cured |
| Syphilis (*) | 1 year following the date of confirmed cured |
| Toxoplasmosis (*) | 6 months following the date of clinical recovery |
| Tuberculosis | 2 years following the date of confirmed cured |
| Rheumatic fever | 2 years following the date of cessation of symptoms, unless evidence of chronic heart disease |
| Fever > °C | 2 weeks following the date of cessation of symptoms |
| Flu-like illness | 2 weeks after cessation of symptoms |
| Malaria (*) | |
|---|---|
—individuals who have lived in a malarial area within the first five years of life | 3 years following return from last visit to any endemic area, provided person remains symptom free; may be reduced to 4 months if an immunologic or molecular genomic test is negative at each donation |
—individuals with a history of malaria | 3 years following cessation of treatment and absence of symptoms. Accept thereafter only if an immunologic or molecular genomic test is negative |
—asymptomatic visitors to endemic areas | 6 months after leaving the endemic area unless an immunologic or molecular genomic test is negative |
—individuals with a history of undiagnosed febrile illness during or within six months of a visit to an endemic area | 3 years following resolution of symptoms; may be reduced to 4 months if an immunologic or molecular test is negative |
| West Nile Virus (WNV) (*) | [F128 days after leaving a risk area of locally acquired West Nile Virus unless an individual Nucleic Acid Test (NAT) is negative] |
Textual Amendments
2.2.2.Exposure to risk of acquiring a transfusion-transmissible infectionU.K.
| Defer for 6 months, or for 4 months provided a NAT test for hepatitis C is negative |
| Persons whose behaviour or activity places them at risk of acquiring infectious diseases that may be transmitted by blood. | Defer after cessation of risk behaviour for a period determined by the disease in question, and by the availability of appropriate tests |
2.2.3.VaccinationU.K.
| Attenuated viruses or bacteria | 4 weeks |
| Inactivated/killed viruses, bacteria or rickettsiae | No deferral if well |
| Toxoids | No deferral if well |
| Hepatitis A or hepatitis B vaccines | No deferral if well and if no exposure |
| Rabies | No deferral if well and if no exposure If vaccination is given following exposure defer for one year |
| Tick-borne encephalitis vaccines | No deferral if well and if no exposure |
2.2.4.Other temporary deferralsU.K.
| Pregnancy | 6 months after delivery or termination, except in exceptional circumstances and at the discretion of a physician |
| Minor surgery | 1 week |
| Dental treatment | Minor treatment by dentist or dental hygienist — defer until next day (NB: Tooth extraction, root-filling and similar treatment is considered as minor surgery) |
| Medication | Based on the nature of the prescribed medicine, its mode of action and the disease being treated |
2.3.Deferral for particular epidemiological situationsU.K.
| Particular epidemiological situations (e.g. disease outbreaks) | Deferral consistent with the epidemiological situation (These deferrals should be notified by the competent authority to the European Commission with a view to Community action) |
2.4.Deferral criteria for donors of autologous donationsU.K.
| Serious cardiac disease | Depending on the clinical setting of the blood collection |
| Persons with or with a history of
| Member States may, however, establish specific provisions for autologous donations by such persons |
| Active bacterial infection |
Options/Help
Print Options
PrintThe Whole Directive
PrintThe Whole Annex
PrintThis Division only
Legislation is available in different versions:
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
See additional information alongside the content
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Opening Options
Different options to open legislation in order to view more content on screen at once
More Resources
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the EU Official Journal
- lists of changes made by and/or affecting this legislation item
- all formats of all associated documents
- correction slips
- links to related legislation and further information resources
Timeline of Changes
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
More Resources
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the print copy
- correction slips
Click 'View More' or select 'More Resources' tab for additional information including:
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- links to related legislation and further information resources
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.